Royalty Pharma plc (NASDAQ:RPRX) Shares Purchased by Two Sigma Advisers LP

Two Sigma Advisers LP boosted its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX) by 44.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,033,200 shares of the biopharmaceutical company’s stock after purchasing an additional 936,900 shares during the period. Two Sigma Advisers LP owned about 0.51% of Royalty Pharma worth $85,809,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. Swedbank AB lifted its holdings in shares of Royalty Pharma by 2.0% in the 3rd quarter. Swedbank AB now owns 11,027,370 shares of the biopharmaceutical company’s stock valued at $311,964,000 after buying an additional 213,900 shares during the period. State Street Corp raised its position in Royalty Pharma by 0.3% during the third quarter. State Street Corp now owns 9,516,262 shares of the biopharmaceutical company’s stock valued at $269,215,000 after acquiring an additional 29,451 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Royalty Pharma by 58.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 3,001,603 shares of the biopharmaceutical company’s stock valued at $84,915,000 after acquiring an additional 1,103,341 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Royalty Pharma by 6.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,972,201 shares of the biopharmaceutical company’s stock worth $84,084,000 after purchasing an additional 174,874 shares in the last quarter. Finally, New South Capital Management Inc. grew its stake in shares of Royalty Pharma by 5.0% during the 3rd quarter. New South Capital Management Inc. now owns 2,466,371 shares of the biopharmaceutical company’s stock worth $69,774,000 after purchasing an additional 117,394 shares during the period. 54.35% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

RPRX has been the topic of several analyst reports. Citigroup dropped their price target on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. The Goldman Sachs Group raised their target price on Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Finally, StockNews.com raised Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $41.67.

Royalty Pharma Stock Performance

NASDAQ RPRX opened at $26.39 on Friday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.54 and a quick ratio of 1.54. The stock’s 50 day simple moving average is $27.03 and its 200-day simple moving average is $27.29. The company has a market cap of $15.55 billion, a PE ratio of 13.67, a price-to-earnings-growth ratio of 4.63 and a beta of 0.46. Royalty Pharma plc has a 1-year low of $25.10 and a 1-year high of $31.66.

Royalty Pharma Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be given a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.18%. The ex-dividend date is Friday, November 15th. Royalty Pharma’s dividend payout ratio (DPR) is 43.52%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.